Pfizer Reports Phase 3 TALAPRO-2 Results for Talzenna in Metastatic CRPC

Pfizer today announced results from the Phase 3 TALAPRO-2 trial evaluating Talzenna (talazoparib) plus enzalutamide in patients with metastatic castration-resistant prostate cancer. The trial met its primary endpoint, demonstrating a significant improvement in radiographic progression-free survival with the combination compared to placebo plus enzalutamide. The risk of radiographic progression or death was reduced by 55% with the combination.